Immunotherapy for Pediatric Gliomas: CAR-T Cells Against B7H3: A Review of the Literature.

IF 2.7 4区医学 Q3 NEUROSCIENCES

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871527322666230406094257

Yolanda Santiago-Vicente, Manuel de Jesús Castillejos-López, Liliana Carmona-Aparicio, Elvia Coballase-Urrutia, Liliana Velasco-Hidalgo, Ana María Niembro-Zúñiga, Marta Zapata-Tarrés, Luz María Torres-Espíndola

{"title":"Immunotherapy for Pediatric Gliomas: CAR-T Cells Against B7H3: A Review of the Literature.","authors":"Yolanda Santiago-Vicente, Manuel de Jesús Castillejos-López, Liliana Carmona-Aparicio, Elvia Coballase-Urrutia, Liliana Velasco-Hidalgo, Ana María Niembro-Zúñiga, Marta Zapata-Tarrés, Luz María Torres-Espíndola","doi":"10.2174/1871527322666230406094257","DOIUrl":null,"url":null,"abstract":"Background: B7H3 is a co-stimulatory molecule for immune reactions found on the surface of tumor cells in a wide variety of tumors. Preclinical and clinical studies have reported it as a tumor target towards which various immunotherapy modalities could be directed. So far, good results have been obtained in hematological neoplasms; however, a contrasting situation is evident in solid tumors, including those of the CNS, which show high refractoriness to current treatments. The appearance of cellular immunotherapies has transformed oncology due to the reinforcement of the immune response that is compromised in people with cancer.Objective: This article aims to review the literature to describe the advancement in knowledge on B7H3 as a target of CAR-T cells in pediatric gliomas to consider them as an alternative in the treatment of these patients.Results: Although B7H3 is considered a suitable candidate as a target agent for various immunotherapy techniques, there are still limitations in using CAR-T cells to achieve the desired success.Conclusion: Results obtained with CAR-T cells can be further improved by the suggested proposals; therefore, more clinical trials are needed to study this new therapy in children with gliomas.","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"420-430"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871527322666230406094257","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: B7H3 is a co-stimulatory molecule for immune reactions found on the surface of tumor cells in a wide variety of tumors. Preclinical and clinical studies have reported it as a tumor target towards which various immunotherapy modalities could be directed. So far, good results have been obtained in hematological neoplasms; however, a contrasting situation is evident in solid tumors, including those of the CNS, which show high refractoriness to current treatments. The appearance of cellular immunotherapies has transformed oncology due to the reinforcement of the immune response that is compromised in people with cancer.

Objective: This article aims to review the literature to describe the advancement in knowledge on B7H3 as a target of CAR-T cells in pediatric gliomas to consider them as an alternative in the treatment of these patients.

Results: Although B7H3 is considered a suitable candidate as a target agent for various immunotherapy techniques, there are still limitations in using CAR-T cells to achieve the desired success.

Conclusion: Results obtained with CAR-T cells can be further improved by the suggested proposals; therefore, more clinical trials are needed to study this new therapy in children with gliomas.

查看原文本刊更多论文

小儿胶质瘤的免疫疗法：针对 B7H3 的 CAR-T 细胞：文献综述。

背景：B7H3 是一种免疫反应共刺激分子，存在于多种肿瘤的肿瘤细胞表面。临床前和临床研究报告称，B7H3 是一种肿瘤靶点，各种免疫疗法都可以针对它进行治疗。迄今为止，血液肿瘤取得了很好的疗效，但包括中枢神经系统肿瘤在内的实体瘤的情况却截然不同，它们对目前的治疗方法表现出很强的抵触情绪。细胞免疫疗法的出现改变了肿瘤学，因为它加强了癌症患者受损的免疫反应：本文旨在回顾文献，描述B7H3作为CAR-T细胞靶点在小儿胶质瘤治疗方面的知识进展，以便将其作为治疗这些患者的替代方案：结果：尽管B7H3被认为是各种免疫治疗技术的合适靶标，但使用CAR-T细胞取得预期成功仍有局限性：结论：CAR-T细胞的治疗效果可以通过建议的方案得到进一步改善；因此，需要进行更多的临床试验，以研究这种针对儿童胶质瘤患者的新疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS & neurological disorders drug targets 医学-神经科学

CiteScore

5.10

自引率

3.30%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.